



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Datasheet for 017-0102**Monkey IgG****Overview**

Description:	Monkey IgG Whole Molecule (BULK ORDER) - 017-0102
Item No.:	017-0102
Size:	2 mg
Applications:	SDS-PAGE, ELISA
Origin:	Monkey

Product Details

Background:	Secreted as part of the adaptive immune response by plasma B cells, immunoglobulin G constitutes 75% of serum immunoglobulins. Immunoglobulin G binds to viruses, bacteria, as well as fungi and facilitates their destruction or neutralization via agglutination (and thereby immobilizing them), activation of the compliment cascade, and opsonization for phagocytosis. The whole IgG molecule possesses both the F(c) region, recognized by high-afinity Fc receptor proteins, as well as the F(ab) region possessing the epitope-recognition site. Both heavy and light chains of the antibody molecule are present.
Synonyms:	Monkey immunoglobulin G
Species of Origin:	Monkey
Format:	IgG
Type:	Native Protein

Target Details

Purity/Specificity:	Monkey IgG whole molecule was prepared from normal serum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Monkey IgG whole molecule was assayed by immunoelectrophoresis resulted in a single precipitin arc against anti-Monkey IgG and anti-Monkey Serum.
Relevant Links:	<ul style="list-style-type: none">017-0102 SDS

Application Details

Tested Applications:	SDS-PAGE
Suggested Applications:	ELISA (Based on references)
Application Note:	Monkey IgG whole molecule has been tested by SDS-Page and can be utilized as a control or standard reagent in SDS, Western Blotting, and ELISA experiments.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	User Optimized
IHC:	User Optimized
WB:	User Optimized


Formulation

Physical State:	Lyophilized
Concentration:	2.2 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None
Reconstitution Volume:	1.0 mL
Reconstitution Buffer:	Restore with deionized water (or equivalent)

Shipping & Handling


Shipping Condition:	Ambient
Storage Condition:	Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Monkey IgG whole molecule is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



ELISA

Humoral immune response. Plasmas were analyzed before vaccination (week 0, pre-immune) and at weeks 1, 2, 4 and 6 post-vaccination for anti-VSV antibodies. Neutralizing antibody (NA) titer (left panel) was defined as the dilution of serum that inhibited infection of mouse EL4 cells with M51R-eGFP by 50%. IgM [p/n 017-0107] (middle panel) and IgG [p/n 017-0102] (right panel) levels are expressed in ng/mL (mean \pm SD, triplicate values), measured by ELISA with extrapolation from standard curves. Data for low dose (a) and high dose (b) vaccinations with M51R and M51R-F are shown. Note scale differences for low and high dose data. Statistical significance was determined by two-factor analysis of variance with cohort and time as the two factors. For all three antibody types, statistical significance of $p < 0.05$ (after correction for multiple comparisons) was obtained for comparisons of cohort 1 versus cohort 3 (low dose M51R vs. M51R-F), cohort 1 versus cohort 2 (low dose M51R vs. high dose M51R), and cohort 3 versus cohort 4 (low dose M51R-F vs. high dose M51R-F), but not for cohort 2 versus cohort 4 (high dose M51R vs. high dose M51R-F). The data shown represent 1 of 2 analyses with similar results performed on plasma from each animal. Figure 1. PMID: 29562688.



SDS-PAGE

SDS PAGE of Monkey IgG Whole Molecule. Lane 1: Non-Reduced Monkey IgG Whole Molecule. Lane 2: 5 μ L Opal Prestained Marker (MB-210-0500). Lane 3: Reduced Monkey IgG Whole Molecule. Load: 1 μ g per lane. Predicted/Observed size: Non-Reduced at 160 kDa, Observed at greater than 180; Reduced at 55, 25 kDa. Non-reduced sample migrates higher due to large molecular weight.

References

- Smith TJ. et al. Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer. *Mol Ther.* (2024)
- Westcott MM et al. Immunogenicity in African green monkeys of m protein mutant vesicular stomatitis virus vectors and contribution of vector-encoded flagellin. *Vaccines (Basel).* (2018)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.